KNSA.NASDAQ
- Kiniksa Pharmaceuticals International, plc
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.75/1.11
|
|
企业价值
3.48B
|
| 资产负债 |
|
每股账面净值
7.42
|
| 现金流量 |
|
现金流量率
0.04
|
| 损益表 |
|
收益
677.56M
|
|
每股收益
3.25
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |

44.9 
